Inactive Instrument

Acasti Pharma Inc. Toronto S.E.

ACST

CA00430K8730

Acasti Pharma Announces Change to Board of Directors

January 16, 2018 at 06:34 pm IST

Acasti Pharma Inc. announced that Neptune's representatives, Rick Schottenfeld and Katherine Crewe, have resigned from Acasti's Board of Directors.

Latest news about Acasti Pharma Inc.

Acasti Pharma Inc. Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-On Safety Trial	28/06	CI
Acasti Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	21/06	CI
Acasti Pharma Inc. to Attend BIO International Convention 2024	29/05	CI
Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	12/02	CI
Craig-Hallum Initiates Acasti Pharma With Buy Rating, $6 Price Target	07/02	MT
Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial	01/02	CI
Acasti Pharma Inc. Approves Appointment of Robert J. Delaversano, as Principal Financial Officer and Principal Accounting Officer	08/01	CI
Acasti Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	13/11	CI
Aker BioMarine Gains Krill Assets from Acasti Pharma in $3.1 Million Settlement Deal	24/23/24	MT
Acasti Pharma Inc. Announces Board Changes	12/23/12	CI
Transcript : Acasti Pharma Inc. - Special Call	11/23/11
Transcript : Acasti Pharma Inc. - Shareholder/Analyst Call	10/23/10
Acasti Pharma Insider Bought Shares Worth $1,249,934, According to a Recent SEC Filing	28/23/28	MT
Acasti Pharma Inc. announced that it has received $7.499388 million in funding from SS Pharma LLC, Shore Pharma LLC	25/23/25	CI
Acasti Pharma Inc. announced that it expects to receive $7.499388 million in funding from SS Pharma LLC, Shore Pharma LLC	24/23/24	CI
Acasti Pharma Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	11/23/11	CI
Top Midday Decliners	07/23/07	MT
Acasti Pharma to Implement 1-for-6 Reverse Stock Split	07/23/07	MT
Acasti Pharma Inc. Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol	06/23/06	CI
Acasti Pharma Says it has Aligned With FDA Protocol for Phase 3 Trial of GTX-104; Receives New Drug Application Guidance	05/23/05	MT
Acasti Pharma, FDA Agree on GTX-104 Phase 3 Trial Protocol	05/23/05	DJ
Acasti Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23/23/23	CI
Acasti Pharma Inc. Announces Scientific Advisory Board Appointments	22/23/22	CI
Acasti Pharma Inc. Terminates the Employment of Brian Ford, Chief Financial Officer	12/23/12	CI
Acasti Pharma Inc. Announces Executive Changes	12/23/12	CI

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Companyâs clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+61.62%	86TCr
NOVO NORDISK A/S	+38.95%	63TCr
JOHNSON & JOHNSON	-3.69%	36TCr
MERCK & CO., INC.	+14.92%	32TCr
ABBVIE INC.	+9.06%	30TCr
ROCHE HOLDING AG	+5.89%	23TCr
NOVARTIS AG	+16.53%	23TCr
AMGEN INC.	+15.75%	18TCr
PFIZER, INC.	+2.43%	16TCr

Other Pharmaceuticals